Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;19(Suppl C):C2-C7.
doi: 10.1093/eurheartj/sux001. Epub 2017 Mar 8.

The inodilator levosimendan as a treatment for acute heart failure in various settings

Finn Gustafsson  1 , Fabio Guarracino  2 , Robert H G Schwinger  3
Affiliations

The inodilator levosimendan as a treatment for acute heart failure in various settings

Finn Gustafsson et al. Eur Heart J Suppl. 2017 Mar.

Abstract

Levosimendan is an inodilator developed for treatment of acute heart failure. It was shown to enhance cardiac contractility, and to exert a vasodilatory effect in all vascular beds. In some trials, the use of levosimendan was associated with cardioprotective effects. These distinctive qualities may be relevant to its use in a range of acute heart failure settings and/or complications, including acute coronary syndromes and cardiogenic shock. It is conjectured that part of the benefit of levosimendan may arise from restoration of ventriculo-arterial coupling via optimization of the ratio of arterial to ventricular elastance and the transfer of mechanical energy. Full confirmation of the effectiveness of levosimendan is still awaited in many of these scenarios; however, the range of potential applications highlights both the versatility of levosimendan and the relative lack of proven interventions in many of these situations.

Keywords: Acute coronary syndromes; Cardiogenic shock; Inodilator; Left ventricular assist device; Levosimendan; Pulmonary hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Derivation of arterial elastance (Ea) and ventricular elastance (Ees) for the assessment of ventriculo-arterial coupling efficiency. The pressure–volume loop area is shaded. The slopes of Ees and Ea are shown. See text for further discussion. LVESV, left ventricular end-systolic volume; LVESP, left ventricular end-systolic pressure; LVEDV, left ventricular end-diastolic volume; LVEDP, left ventricular end-diastolic pressure; LV, left ventricular; SV, stroke volume; V0, theoretical volume when no pressure is generated. Reproduced with permission from Guarracino et al.
Figure 2
Figure 2
The GFR response to inodilatation may be used to guide a patient’s eligibility for a place on the heart transplant register. HTX, heart transplantation; ACE-I, angiotensin-converting enzyme inhibitor; GFR, glomerular filtration rate; BB, beta-blockers; BP, blood pressure; sys, systolic.
See this image and copyright information in PMC

References

    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975. - PubMed
    1. Brixius K, Reicke S, Schwinger RH.. Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol 2002;282:H131–H137. - PubMed
    1. Pollesello P, Papp Z, Papp JG.. Calcium sensitizers: what have we learned over the last 25 years? Int J Cardiol 2016;203:543–548. - PubMed
    1. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W.. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000;102:2222–2227. - PubMed
    1. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ.. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903–1912. - PubMed